Syngene International’s Board has approved significant leadership changes effective mid-2026. Ms. Kiran Mazumdar Shaw will transition from Non-Executive Chairperson to Executive Chairperson, effective April 1, 2026. Concurrently, Mr. Peter Bains will resign as Managing Director & CEO on June 30, 2026. Mr. Siddharth Mittal has been appointed as the new MD & CEO, effective July 01, 2026.
Executive Leadership Overhaul Announced
Syngene International Limited has formally announced a series of critical changes within its leadership structure, all approved by the Board of Directors following recommendations from the Nomination and Remuneration Committee (NRC).
Transition of Chairperson Role
Effective from April 01, 2026, Ms. Kiran Mazumdar Shaw will assume the role of Executive Chairperson for a period of 5 years. This constitutes a change in status from her prior role as Non-Executive Chairperson, making her a Key Managerial Personnel (KMP) of the Company.
- Brief Profile: Ms. Shaw is the founder of the Biocon Group and has over four decades of experience in biotechnology, leading Biocon into a global biopharmaceutical enterprise.
Resignation of MD & CEO
Mr. Peter Bains has resigned from his dual role as Managing Director & Chief Executive Officer of the Company. His resignation is effective from the close of business hours on June 30, 2026.
Appointment of New MD & CEO
The Board has appointed Mr. Siddharth Mittal as an Additional Director, who will simultaneously take over as the new Managing Director & Chief Executive Officer, effective July 01, 2026. This appointment is for a period of 5 years and designates him as a Key Managerial Personnel (KMP).
- Prior Experience: Before this role, Mr. Mittal served as Managing Director and CEO of Biocon Limited, having joined in May 2013. He brings over two decades of experience in strategic finance, M&A, and general management, contributing significantly to Biocon’s expansion into biosimilars and complex peptides.
Compliance and Disclosure Confirmation
The Company confirms that Mr. Siddharth Mittal is not subject to any debarment order from the Securities and Exchange Board of India (SEBI) or any other authority, in accordance with existing circular guidelines.
All relevant disclosures required under Regulation 30 are enclosed in Annexure 1 of the official filing, and the information will also be hosted on the Company website.
Source: BSE
